Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLD-HAIC: GemOX HAIC + Lenvatinib + Toripalimab for Advanced ICC and GBC
NCT06852287Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, lenvatinib, gemcitabine and oxaliplatin in intrahepatic cholangiocarcinoma (ICC) and gallbladder cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate at 1 year. Started Sep 2024; status: recruiting.
02
Drugs
toripalimablenvatinibgemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)gallbladder cancer
Beyond the preview
Go deeper on NCT06852287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06852287.